Konica Minolta has provided an update regarding the transfer of its subsidiary, Ambry Genetics Corporation, to Tempus AI, Inc. The transaction, completed on February 3, 2025, involved a sale price of US$600 million, with US$375 million paid in cash and US$225 million in Tempus Class A Common stock. Of the stock portion, US$125 million became available for sale after the registration process and was fully sold during the first quarter of the fiscal year ending March 2026. The remaining US$100 million in stock was originally subject to a one-year lock-up, but the terms have been amended so that these shares are now subject to certain restrictions on sale on and after December 2, 2025, and will become freely saleable one year after the transaction's closing date.